What Grand Pharmaceutical Group does

Grand Pharmaceutical Group is a Chinese specialty pharmaceutical company listed on the Hong Kong Stock Exchange (SEHK:512) and headquartered in Hong Kong, with operations spanning vascular drugs, ophthalmic drugs, and radiopharmaceuticals. Founded in 1995 and operating with 10,000+ employees, the company pursues a hybrid model that combines proprietary product ownership via acquisition (87.5% of U.S.-based BlackSwan Vascular, including the FDA-approved vascular treatment LavaTM, acquired for $37.5 million in 2023) with exclusive regional licensing and commercialization partnerships for Western pipelines in Greater China. Key licensed/partnered assets include TP-03 (lotilaner ophthalmic solution 0.25%, branded XDEMVY in the U.S.), licensed from Tarsus Pharmaceuticals and approved by China's NMPA in March 2026 for Demodex blepharitis — a condition affecting more than 40 million people in Greater China — and a suite of Telix radiopharmaceutical imaging candidates including TLX591-CDx (Illuccix) for prostate cancer. The company also holds a 40% stake in Minnesota-based FastWave following a $12 million investment.

The company's revenue model derives primarily from pharmaceutical product sales and licensing royalties in Greater China, augmented by milestone payments triggered by regulatory events (e.g., the $15 million Tarsus milestone tied to NMPA approval of TP-03) and equity returns from its U.S. portfolio companies. Go-to-market is enterprise/regulatory-driven rather than consumer-facing: the firm uses exclusive licensing partnerships and direct NMPA engagement rather than direct-to-consumer marketing, and it maintains U.S. government relations capacity (including lobbying engagement on CFIUS matters) to protect cross-border investment positions.

Customer-facing reach is through healthcare providers and patients in the Greater China region across two primary therapeutic verticals: ophthalmology (Demodex blepharitis, with GPN01768 as a second ophthalmic asset) and oncology imaging (prostate cancer radiopharmaceuticals). The company's value proposition to partners is its NMPA regulatory expertise and access to the large Chinese patient population, while its value proposition to Chinese patients is earlier access to globally innovative, first-in-class or only-approved therapies that would otherwise be unavailable domestically.

Name

Grand Pharmaceutical Group

Legal name

Grand Pharmaceutical Group Limited

Website

https://grandpharm.com

Company type

Public

Founded year

1995

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Grand Pharmaceutical Group is a Hong Kong-listed Chinese specialty pharmaceutical company (SEHK:512) that develops and commercializes vascular, ophthalmic, and radiopharmaceutical drugs in Greater China through acquisitions and exclusive licensing partnerships with Western biotech firms.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

akta.pro secondary industries

Ophthalmology Pharmaceuticals (HLAIAAAL), Ophthalmology Specialty Pharmaceuticals (HLAIACAK), Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE), Cardiology & Vascular Specialty Pharmaceuticals (HLAIACAG)

Keywords

• Pharmaceutical development
• Ophthalmic therapeutics
• Vascular drug treatments
• Radiopharmaceutical imaging
• Drug commercialization licensing

Headquarters

HQ city

Central

HQ country

Hong Kong SAR China

HQ region

Asia

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Technology or R&D, Marketing or Sales, Personnel, Others

Revenue model

1. Drug development and commercialization: Grand Pharmaceutical Group develops and commercializes pharmaceutical products globally, with a focus on vascular treatments, ophthalmic drugs, and radiopharmaceuticals. Revenue is generated through product sales and licensing agreements.
2. Investment returns from U.S. portfolio companies: The company holds stakes in U.S. startups including a 40% stake in FastWave, generating returns through equity appreciation and strategic value from its portfolio companies.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels1 record

Core offering

Grand Pharmaceutical Group develops, licenses, and commercializes pharmaceutical products focused on vascular drugs, ophthalmic therapeutics, and radiopharmaceutical imaging agents for the Greater China market and globally. The company combines proprietary assets acquired through international M&A (e.g., LavaTM via BlackSwan Vascular) with exclusive regional licensing rights to first-in-class approved therapies (e.g., TP-03/XDEMVY). It also pursues strategic equity investments in U.S. biotech startups to access innovative pipeline assets.

Product overview

Grand Pharmaceutical Group is a Chinese pharmaceutical company listed on SEHK (stock code 512) that operates as an integrated pharmaceutical business with a portfolio of acquired and licensed products. The company pursues global expansion through acquisitions of international companies and strategic partnerships for drug commercialization. Key products include LavaTM (an FDA-approved vascular treatment from acquired BlackSwan Vascular), TP-03 (an ophthalmic solution for Demodex blepharitis licensed for the Greater China region), and GPN01768 (an approved ophthalmic drug). The company has invested in U.S. startups including FastWave and maintains partnerships with companies like Tarsus Pharmaceuticals and Telix Pharmaceuticals for product development and commercialization in the Chinese market.

Differentiator

Problem solved

Functional benefit

Products and services

• LavaTM FDA-approved vascular treatment developed by BlackSwan Vascular for vascular conditions. Grand Pharmaceutical Group acquired 87.5% of BlackSwan Vascular for $37.5 million to add this proprietary therapeutic asset to its portfolio.
• TP-03 (lotilaner ophthalmic solution) 0.25% Ophthalmic solution approved by China's National Medical Products Administration (NMPA) for the treatment of Demodex blepharitis. Marketed as XDEMVY in the U.S. by Tarsus Pharmaceuticals. Grand Pharmaceutical Group serves as the exclusive partner for development and commercialization in the Greater China region, where the condition affects more than 40 million people.
• GPN01768 Ophthalmic drug approved for the Chinese market, referenced in connection with Grand Pharmaceutical Group's full year 2025 earnings results.
• TLX591-CDx (Illuccix) Prostate cancer radiopharmaceutical imaging agent undergoing Phase 3 study in Chinese patients. Being developed with Telix Pharmaceuticals to support a near-term NDA submission in China.

Quantifiable outcome

• TP-03 (Xdemvy) approved for Demodex blepharitis in China, addressing a condition affecting over 40 million people in Greater China

Named customers2 records

Segments2 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Four partnerships are on record, tiered core and minor.

• Tarsus PharmaceuticalscoreStrategic or Co-development Partner · 23 March 2026Grand Pharmaceutical Group is the exclusive partner of Tarsus Pharmaceuticals for development and commercialization of TP-03 (lotilaner ophthalmic solution) in the Greater China region. The NMPA approval of TP-03 for Demodex blepharitis triggered a $15 million milestone payment for Tarsus. TP-03 is the first and only therapy approved to address the root cause of Demodex blepharitis, a condition affecting more than 40 million people in the region.
• Checkmate (Lobbying Firm)minorGTM or Marketing Partner · 1 January 2026Grand Pharmaceutical Group hired Checkmate, a lobbying firm with personal ties to Donald Trump Jr., to lobby CFIUS and senior U.S. Treasury officials on its behalf regarding its investment in FastWave. The firm helped secure a meeting with CFIUS leadership to argue against national security review of the investment.
• Telix PharmaceuticalscoreStrategic or Co-development Partner · 22 December 2025Grand Pharmaceutical Group is a strategic partner with Telix Pharmaceuticals for the development and commercialization of radiopharmaceutical products including TLX591-CDx (Illuccix), TLX101-CDx, and TLX250-CDx in China. Positive Phase 3 study results for TLX591-CDx in Chinese prostate cancer patients support near-term NDA submission in China.
• BlackSwan VascularcoreStrategic or Co-development Partner · 25 April 2023Grand Pharmaceutical Group acquired 87.5% of U.S.-based BlackSwan Vascular for $37.5 million. The acquisition supports Grand Pharma's global expansion strategy and follows FDA approval of BlackSwan's treatment LavaTM. BlackSwan had previously been acquired by Sirtex Medical in 2020.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• CSPC Pharmaceutical Group: CSPC is a Hong Kong-listed Chinese pharmaceutical company with a diversified portfolio of branded specialty drugs, including cardiovascular and oncology products. It is directly comparable to Grand Pharma in scale, business model (innovator + licensed specialty pharma), and Greater China market focus.
• Sino Biopharmaceutical Limited: Sino Biopharm is a Hong Kong-listed Chinese pharma group with branded specialty therapeutics across hepatology, oncology, and cardiovascular areas. It is highly comparable to Grand Pharma in therapeutic mix, listing jurisdiction, and emphasis on innovative branded products for the China market.
• China Medical System Holdings: China Medical System is a Hong Kong-listed specialty pharma focused on licensing and commercialization of innovative drugs for the Chinese market, with a similar asset-light, partnership-driven model. Comparable to Grand Pharma's exclusive licensing strategy with Tarsus and Telix.
• Shanghai Fosun Pharmaceutical: Fosun Pharma is a major Chinese pharmaceutical group with both domestic and overseas operations, including cross-border M&A (e.g., Gland Pharma). Its global expansion strategy and mix of licensing, manufacturing, and specialty therapeutics make it a direct strategic comparable to Grand Pharma.
• Jiangsu Hengrui Pharmaceuticals: Hengrui is China's largest innovative pharmaceutical company with a deep specialty drug pipeline in oncology, anesthesia, and contrast media. Comparable to Grand Pharma in its focus on innovative branded pharmaceuticals and global commercialization ambitions.

Emerging players

• Tarsus Pharmaceuticals: Tarsus is the originator of TP-03 (lotilaner ophthalmic solution), Grand Pharma's exclusive Greater China partner. While a commercial-stage peer in ophthalmology, its primary role here is as a partner whose pipeline underpins Grand Pharma's ophthalmology growth.
• Telix Pharmaceuticals: Telix is a commercial-stage radiopharmaceutical company whose Illuccix and pipeline assets Grand Pharma commercializes in China. Overlap with Grand Pharma exists in the radiopharmaceutical imaging category, though Telix's primary markets are Western geographies.

Regional players

• Sirtex Medical: Sirtex is a radiopharmaceutical-focused company (acquired by Chinese investors in 2018) that previously owned BlackSwan Vascular before Grand Pharma's acquisition. Its prior ownership chain and presence in interventional oncology make it an adjacent comparable for Grand Pharma's radiopharma ambitions.

Broad incumbents

• Novartis AG: Novartis operates a broad specialty pharma portfolio including ophthalmology (e.g., Beovu) and radiopharmaceuticals (Pluvicto) that overlap with Grand Pharma's therapeutic areas. It competes in the same China commercial landscape but at vastly larger scale and with proprietary R&D rather than licensing.
• Bayer AG: Bayer is a diversified life sciences incumbent with significant ophthalmology (Eylea) and cardiovascular franchises. It competes with Grand Pharma in China specialty therapeutics and is a representative of the global incumbents whose products Grand Pharma often licenses or competes against.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/grand-pharmaceutical-group-limited

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Grand Pharmaceutical Group